20+ Years of Evidence

Join the experts’ corner

The Accuray innovations showcased at ASTRO/ESTRO 2021 are all technologies that build on more than two decades of clinical evidence and real-world use. Don’t take our word for it — hear the proof directly from your expert peers:

ESTRO Abstracts

Breast

  • PD-0779: Fiducial motion relative to tumor bed in partial breast irradiation and risk of geographical miss. N. Hoekstra1, S. Habraken1, A. Swaak – Kragten1, J. Pignol2, M. Hoogeman1. 1Erasmus MC Cancer Institute, Radiotherapy, Rotterdam, The Netherlands; 2Dalhousie University,
    Radiotherapy, Halifax, Canada
  • PO-1138: Preoperative radiation therapy in breast cancer: preliminary results from ROCK trial (NCT03520894). V. Di Cataldo1, G. Francolini2, L. Visani1, C. Becherini2, E. Scoccimarro3, L. Masi1, R. Doro1, G. Salvatore4, S.Bianchi5, V. Vezzosi6, E. Lemmi6, J. Nori7, L. Sanchez8, L. Orzalesi8, M. Bernini8, M. Loi2, I. Desideri4, M.Mangoni4, I. Meattini4, L. Livi4. 1IFCA, Cyberknife, Florence, Italy; 2Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Oncology Department, Florence, Italy; 3University of Florence, Department of Experimental and Clinical Biomedical Sciences Mario Serio, Florence, Italy; 4University of Florence, Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, Florence, Italy; 5 Azienda Ospedaliero-Universitaria Careggi, Division of Pathological Anatomy, Florence, Italy; 6Azienda Ospedaliero-Universitaria Careggi, Division of Pathological Anatomy, Florence, Italy; 7Azienda Ospedaliero-Universitaria Careggi, Diagnostic Senology Unit, Florence, Italy; 8Azienda Ospedaliero-Universitaria Careggi, Breast Surgery Unit, Florence, Italy

  • PO-1087: Hypofractionated radiotherapy for breast cancer orbital lesion: a multicentric series of 35 patients. I. Desideri1, L.P. Ciccone1, G. Piperno2, M. Augugliaro2, B.A. Jereczek-Fossa3, P. Navarria4, L. Dominici5, M. Scorsetti6, V. Salvestrini1, G. Riva7, V. Di Cataldo8, L. Visani8, M. Loi9, I. Meattini10, L. Livi10. 1University of Florence, Department of Experimental and Clinical Biomedical Sciences “M. Serio”, Florence, Italy; 2 IEO European Institute of Oncology, IRCCS, Division of Radiotherapy, Milan, Italy; 3University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy. IEO European Institute of Oncology, IRCCS, Division of Radiotherapy, Milan, Italy; 4Humanitas Research Hospital-IRCCS, Radiotherapy and Radiosurgery department , Rozzano, Milan, Italy; 5Humanitas Research Hospital-IRCCS, Radiotherapy and Radiosurgery department, Rozzano, Milan, Italy; 6Humanitas Research Hospital-IRCCS, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele , Milan, Italy; 7National Center for Oncological Hadrontherapy (CNAO), Radiotherapy Unit, Pavia, Italy; 8 Istituto Fiorentino di Cura ed Assistenza, CyberKnife Center, Florence, Italy; 9Azienda Ospedaliero Universitaria Careggi, Radiation Oncology Unit – Oncology Department, Florence, Italy; 10University of Florence, Department of Experimental and Clinical Biomedical Sciences “M. Serio”. Azienda Ospedaliero Universitaria Careggi, Radiation Oncology Unit – Oncology Department, Florence, Italy

Brain

  • PO-1775: Effect of intra-fraction patient stability on treatment margins in brain SRS with Cyberknife. D. Sevillano1, J.D. García-Fuentes1, M. Cámara1, E. Fernández-Lizarbe2, M. Martín-Sánchez2, C. De la Pinta2, R. Colmenares1, B. Capuz1, R. Morís1, F. Orozco1, P. Retorta1, P. Galiano1, M.J. Béjar1, D. Prieto1, F. GarcíaVicente1. 1H. U. Ramón y Cajal, Medical Physics, Madrid, Spain; 2H. U. Ramón y Cajal, Radiation Oncology, Madrid, Spain
  • PO-1047 : Prospective evaluation of 167 brain metastases in Indian patients treated with robotic radiosurgery. S. K1, R. Kamath1, A. Gupte1, A. Sasidharan1, P. K U1, A. R1, H. Nair1, A. E H2, D. Dutta1. 1Amrita Institute of Medical Sciences, Radiation Oncology, Kochi, India; 2Amrita Institute of Medical Sciences, Medical Physics, Kochi, India
  • PO-1069: Multiple Brain Metastases concomitantly treated with robotic SRS/SRT. A. Sanchez Galvan1, A.M. Deli2, A. Fodor2, R. Tummineri2, S.L. Villa3, S. Baroni4, G. Mandurino5, P. Pacifico3, C.L. Deantoni2, N. Slim2, F. Zerbetto2, C. Fiorino6, S. Broggi6, A. Del Vecchio6, S. Arcangeli7, N.G. Di Muzio8. 1 IRCCS San Raffaele Scientific Institute , University of Milano-Bicocca, Radiation Oncology, Milano, Italy; 2 IRCCS San Raffaele Scientific Institute, Radiation Oncology, Milan, Italy; 3 IRCCS San Raffaele Scientific Institute, University of Milano-Bicocca, Radiation Oncology, Milan, Italy; 4 IRCCS San Raffaele Scientific Institute , University of Milano-Bicocca, Radiation Oncology, Milan, Italy; 5 IRCCS San Raffaele Scientific Institute, University of Milano-Bicocca, Radiation Oncology, Milan, Italy; 6 IRCCS San Raffaele Scientific Institute, Medical Physics, Milan, Italy; 7University of Milano-Bicocca, Radiation Oncology, Milan, Italy; 8 IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Radiation Oncology, Milan, Italy 
  • PO-1025: Outcomes of re-irradiation of relapsed intracranic lesions with stereotactic radiotherapy. R. Tummineri1, A. Fodor2, A. Sanchez Galvan3, S.L. Villa3, S. Baroni3, G. Mandurino3, P. Pacifico3, C.L.Deantoni2, F. Zerbetto2, A.M. Deli2, S. Broggi4, A. Del Vecchio5, N.G. Di Muzio6. 1 IRCCS San Raffaele Institute, Radiation Oncology, Milano, Italy; 2IRCCS San Raffaele Scientific Institute,Radiation Oncology, Milano, Italy; 3Milano-Bicocca University, Radiation Oncology, Milano, Italy; 4 IRCCS San Raffaele Scientific Institute, Medical Physics, Milano, Italy; 5 IRCCS San Raffaele Scientific Institute, ;edicalPhysics, Milano, Italy; 6IRCCS San  Raffaele Scientific Institute – Vita e Salute San Raffaele University, Radiation Oncology, Milano, Italy 

Spine

  • PO-1444: Determinants of radioresistance and progression-free interval in SBRT-treated spinal metastases. M. Aquilano1, S. Lucidi1, L. Mauro2, G. Francolini3, G. Simontacchi2, D. Greto2, I. Desideri4, P. Bonomo2, A.G. Allegra1, M. Mariotti1, L. Masi5, R. Doro5, I. Bonucci6, V. Di Cataldo6, M. Mangoni1, L. Livi1. 1University of Florence, Department of Experimental and Clinical Biomedical Sciences “M. Serio”, Florence, Italy; 2Azienda Ospedaliero-Universitaria Careggi, Department of Radiation Oncology, Florence, Italy;3Azienda Ospedaliero-Universitaria Careggi, Department of Radiation Oncology, Florence, Italy; 4University of Florence, Department of Experimental and Clinical Biomedical Sciences “M. Serio” , Florence, Italy; 5Radiation Oncology IFCA, Department of Medical Physics, Florence, Italy; 6Radiation Oncology IFCA, Department of Radiation Oncology, Florence, Italy 

Vestibular Schwannoma

Liver

Pancreas

Rectal

  • PO-1262: Outcomes in locally recurrent rectal cancer treated with reirradiation stereotactic ablative radiotherapy (SABR). R. Muirhead1,1, K. Aitken2, J. Holmes3, M. Harrison4, D. Harji5, S. O’Cathail6, C. Taylor7, M. Wing8. 1Oxford University Hospitals NHS Foundation Trust, Department of Oncology, Oxford, United Kingdom; 2The Royal Marsden Hospital, Fulham Road, Department of Oncology, London, United Kingdom; 3University of Oxford, Centre for Statistics in Medicine, Oxford, United Kingdom; 4Mount Vernon Hospital, Mount Vernon for Cancer Treatment, Northwood, United Kingdom; 5University of Leeds, Department of Colorectal Surgery, Leeds, United Kingdom; 6University of Glasgow, Institute of Cancer Sciences, Glasgow, United Kingdom; 7
    St Mark’s Hospital, Department of Colorectal Surgery, London, United Kingdom; 8Bowel Cancer UK, Patient Representative, London, United Kingdom

Renal Cell Carcinoma

Prostate

  • PD-0764: Quality of life, toxicity, and PSA control after 50 Gy SBRT to the dominant intraprostatic nodule. M. Cloitre1, M. Valerio2, B. Roth2, D. Berthold 3, T. Tawadros2, J. Meuwly4, L. Heym1, F. Duclos 5, S. ViguetCarrin 6, V. Vallet 1, J. Bourhis5, F. Herrera1. 1Lausanne University Hospital , Radiation Oncology, Lausanne, Switzerland; 2Lausanne University Hospital , Urology, Lausanne, Switzerland; 3Lausanne University Hospital , Oncology, Lausanne, Switzerland; 4Lausanne University Hospital , Radiology and Interventional Radiology, Lausanne , Switzerland; 5Lausanne University Hospital , Radiation Oncology, Lausanne , Switzerland; 6Lausanne University Hospital , Center for Experimental Therapeutics, Lausanne , Switzerland
  • OC-0289: Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy). A.C. Tree1, E. Hall2, P. Ostler3, H. van der Voet4, A. Loblaw5, W. Chu5, D. Ford6, S. Tolan7, S. Jain8, A. Martin9, J. Staffurth10, P. Camilleri11, K. Kancherla12, J. Frew13, D.H. Brand14, A. Chan15, I.S. Dayes16, S. Brown2, J. Pugh2, S. Burnett2, A. Dufton17, C. Griffin2, M. Mahmud2, O. Naismith1, N. van As1, O.B. of the18. 1The Royal Marsden NHS Foundation Trust, Department of Oncology, London, United Kingdom; 2The Institute of Cancer Research, Clinical Trials and Statistics Unit, London, United Kingdom; 3Mount Vernon Cancer Centre, Department of Oncology, Northwood, United Kingdom; 4The James Cook University Hospital, Department of Oncology, Middlesbrough, United Kingdom; 5Odette Cancer Centre, Sunnybrook Health Sciences Centre,Department of Oncology, Toronto, Canada; 6University Hospitals Birmingham, Department of Oncology, Birmingham, United Kingdom; 7The Clatterbridge Cancer Centre, Department of Oncology, Birkenhead, United Kingdom; 8Queen’s University Belfast, Department ofOncology, Belfast, United Kingdom; 9West Suffolk and Addenbrooke’s Hospitals, Department of Oncology, Cambridge, United Kingdom; 10Velindre Cancer Centre, Department of Oncology, Cardiff, United Kingdom; 11Churchill Hospital, Department of Oncology, Oxford, United Kingdom; 12University Hospitals of Leicester, Department of Oncology, Leicester, United Kingdom; 13Freeman Hospital, Department of Oncology, Newcastle, United Kingdom; 14The Institute of Cancer Research, Uro-Oncology Unit, London, United Kingdom; 15University Hospitals Coventry & Warwickshire, Department of Oncology, Coventry, United Kingdom; 16Juravinski Cancer Centre, Division of Radiation Oncology, Hamilton, Canada; 17Beatson West of Scotland Cancer Centre, Department of Oncology, Glasgow, United Kingdom; 18PACE , Trial Investigators, London, United Kingdom
  • OC-0509: 10-year outcome of ultrahypofractionated stereotactic RT from two multicenter prostate cancer trials. R. Meier1, I. Kaplan2, D. Bloch3, R. Chen4, B. Kane5, G. Henning6, S. Woodhouse7, T. Royce8, C. Cotrutz9, D. Fuller10. 1 Swedish Cancer Institute, Radiation Oncology, Seattle, USA; 2Beth Israel Deaconess Medical Center, Radiation Oncology, Boston, USA; 3 Stanford University, Biomedical Data Science, Stanford, USA; 4University of Kansas, Radiation Oncology, Lawrence, USA; 5Community Medical, Radiation Oncology, Fresno, USA; 6 St. Joseph Mercy, Radiation Oncology, Ann Arbor, USA; 7Carle Cancer Institute, Radiation Oncology, Normal, USA; 8UNC Health, Radiation Oncology, Chapel Hill, USA; 9 Swedish Cancer Institute, Swedish Radiosurgery Center, Seattle, USA; 10Genesis Healthcare Partners, Radiation Oncology, San Diego, USA 
  • PO-1316: Stereotactic radiotherapy in recurrent prostate cancer after postoperative or definitive irradiation. G. Francolini1, M. Loi1, V. Di Cataldo2, B. Detti3, G. Stocchi4, A.G. Allegra4, C. Bellini4, M. Aquilano4, L.P. Ciccone4, M. Mariotti4, V. Salvestrini4, E. Scoccimarro5, M. Valzano5, G. Simontacchi3, P. Bonomo3, S. Lucidi4, I. Desideri4, I. Meattini4, L. Livi4. 1Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy; 2 Istituto Fiorentino di Cura e Assistenza (IFCA), Radiotherapy Unit, Florence, Italy; 3 Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy; 4University of Florence, Department of Experimental and Clinical Biomedical Sciences “M. Serio”, Florence, Italy; 5University of Florence, Department of Experimental and Clinical Biomedical Sciences “M. Serio”, Florence, Italy
  • PO-1317: Prostate Cancer Patient Reported Outcome After Cyberknife Robotic Radiosurgery. S. Exner1, F. Fehlauer1. 1Strahlenzentrum Hamburg, Cyberknife Unit, Hamburg, Germany
  • PO-1341: SBRT for Japanese patients with prostate cancer: prediction of acute genitourinary toxicities. M. Ito1, Y. Takase2, J. Suzuki3, T. Matsunaga3, H. Takahashi3, A. Takeuchi1, S. Adachi1, S. Abe1, Y. Oshima1, K. Ohtakara4, Y. Yoshioka5, K. Suzuki1, T. Okuda3. Aichi Medical University Hospital, Radiology, Nagakute, Japan; 2Nagoya University Hospital, Radiology, Nagoya, Japan; 3Toyota Memorial Hospital, Radiation Oncology, Toyota, Japan; 4Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Radiation Oncology, Yatomi, Japan; 5Cancer Institute Hospital of Japanese Foundation for Cancer Research, Radiation Oncology, Koto, Japan
  • PO-1346: Systematic Review of Salvage Reirradiation Options for Locally Recurrent Prostate Cancer. J. Zhong1,2, F. Slevin1,3, A. Scarsbrook1,4, M. Serra5 , A. Choudhury6,5, P. Hoskin6,5,7, S. Brown8 , A. Henry1,3. 1University of Leeds, Leeds Institute of Medical Research, Leeds, United Kingdom; 2Leeds Cancer Centre, Diagnostic and Interventional Radiology, Leeds, United Kingdom; 3Leeds Cancer Centre, Clinical Oncology, Leeds, United Kingdom; 4Leeds Cancer Centre, Radiology and Nuclear Medicine, Leeds, United Kingdom; 5The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom; 6University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom; 7Mount Vernon Centre for Cancer Treatment, Clinical Oncology, London, United Kingdom; 8University of Leeds, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom
  • PO-1364: Bleeding Risk after Prostate SBRT in Men on Baseline Anticoagulant/Antiplatelet Therapy. A. Pepin1, S. Shah2, M. Pernia3, S. Lei1, M. Ayoob1, M. Danner1, T. Yung1, B. Collins1, S. Suy1, N. Aghdam4, S. Collins1. 1Georgetown University, Radiation Medicine, Washington, USA; 2George Washington University, School of Medicine and Health Sciences, Washington, USA; 3George Washington University, Geriatrics, Washington, USA; 4Beth Israel Deaconess, Radiation Oncology, Boston, USA
  • PO-1390: Intra-fraction prostate motion during stereotactic irradiation in 1st irradiation and re-irradiation. A. TAILLEZ1, A.M. Bimbai2, T. Lacornerie3, M. Le Deley2, E.F. Lartigau1, D. Pasquier1. 1Oscar Lambret Center, Academic Department of Radiation Oncology, Lille, France; 2Oscar Lambret Center, Department of Biostatistics, Lille, France; 3Oscar Lambret Center, Department of Medical Physics, Lille, France
  • PO-1539: Daily Plan Verification Before and After Treatment in Prostate Stereotactic Body Radiotherapy. E. Kucukmorkoc1 , N. Kucuk1 , E. Sanli1 , S. Celebi1 , D. Canoglu1 , R. Rzazade1 , M. Turna1 , H.B. Caglar1. 1anadolu Medical Center, Radiation Oncology, Kocaeli, Turkey

Lymph Node

  • PO-1300: Stereotactic Body Radiation Therapy for oligometastatic lymph-nodal relapses in gynecological cancer. G. Mandurino1, A. Fodor2, S.L. Villa1, S. Baroni1, A. Sanchez Galvan1, R. Tummineri3, P. Pacifico1, F. Zerbetto2,C.L. Deantoni2, P. Mangili4, A. Del Vecchio4, S. Arcangeli5, N.G. Di Muzio6. 1 IRCCS San Raffaele Scientific Institute / University of Milano-BIcocca, Radiation Oncology, Milan, Italy; 2 IRCCS San Raffaele Scientific Institute, Radiation Oncology, Milan, Italy; 3 IRCCS San Raffaele Scientific Institute, Radiation Oncolgy, Milan, Italy; 4 IRCCS San Raffaele Scientific Institute, Medical Physics, Milan, Italy; 5University of Milano-BIcocca, Radiation Oncology, Milan, Italy; 6 IRCCS San Raffaele Scientific Institute / “Vita-Salute” San Raffaele University, Radiation Oncology, Milan, Italy

Lung

  • PO-1189: Stereotactic radiotherapy for lung oligometastases from colorectal cancer. A. Fodor1, C.L. Deantoni1, R. Tummineri1, C. Fiorino2,3, I. Dell’Oca1, M. Mori2, S. Broggi2, M. Pasetti1, L. Perna2,S.L. Villa1, G. Mandurino1, A. Sanchez Galvan1, S. Baroni1, P. Pacifico1, A. Del Vecchio2, N.G. Di Muzio1,3. 1 IRCCS San Raffaele Scientific Institute, Department of Radiation Oncology, Milan, Italy; 2 IRCCS San Raffaele Scientific Institute, Medical Physics, Milan, Italy; 3Vita-Salute San Raffaele University, Radiotherapy, Milan, Italy
  • PO-1190: Lung lesions treated with CyberKnife: An Indian single centre experience. A. Sasidharan1, R. Kamath1, P. KU1, A. R1, S. K Reddy1, H. Nair1, A. E H2, D. Dutta1. 1Amrita Institute of Medical Sciences, Radiation Oncology, Kochi, India; 2Amrita Institute of Medical Sciences, Medical Physics, Kochi, India
  • PO-1401: Lung metastasis from renal cell carcinoma: SBRT alone or in association with target therapy as a potential treatment option. F. Zerbetto1, S. Foti2, C. Deantoni1, M. Pasetti3, A. Chiara4, T. Roberta3, S. Broggi5, N.G. Di Muzio6. 1 IRCCS San Raffaele Scientific Institute, Department of Radiotherapy, Milan, Italy; 2 IRCCS San Raffaele Scientific Institute, Department of Medical Oncology, Milan, Italy; 3 IRCCS San Raffaele Scientific Institute, (1) Department of Radiotherapy, Milan, Italy; 4 IRCCS San Raffaele Scientific Institute, Department of Radiotherapy, milan, Italy; 5 IRCCS San Raffaele Scientific Institute, Milan, Italy, Medical Physics, Milan, Italy; 6Vita –Salute S. Raffaele University , (3) Department of Radiotherapy, Milan, Italy

Oligometastases (mixed primaries)

Accelerated Hypofractionated Radiotherapy

CyberKnife Liver

Publications

CyberKnife Pancreas

Publications

TomoTherapy Lung

Publications

TomoTherapy Liver

Publications

IG-IMRT Treatment

TomoTherapy Intracranial

Publications

TomoTherapy Head & Neck

Publications

TomoTherapy Breast

Publications

Videos

TomoTherapy Lung

Publications

TomoTherapy Mesothelioma

Publications

TomoTherapy Liver

Publications

TomoTherapy Bladder

Publications

TomoTherapy Prostate

Publications

Videos

TomoTherapy Gynecological

Publications

TomoTherapy Rectal Cancer

Publications

Videos

TomoTherapy Anal Cancer

Publications

TomoTherapy Sarcoma

Publications

TomoTherapy Superficial

Publications

Long Fields Treatment

TomoTherapy Total Body Irradiation

Publications

Videos

TomoTherapy Total Marrow Irradiation

Publications

Videos

Total Skin Irradiation

Publications

TomoTherapy Pediatrics

Publications

Videos/Slides

Moving Targets Treatment

Motion Synchronization on CyberKnife

Publications

Videos

For more indication specific information, please click here.

Motion Synchronization on Radixact

Publications

Videos

SBRT Treatment

CyberKnife Head and Neck

Publications

CyberKnife Ocular

Publications

CyberKnife Breast

Publications

Videos

CyberKnife Lung

Publications

Videos

CyberKnife Liver

Publications

Videos

CyberKnife Pancreas

Publications

Videos

CyberKnife Kidney

Publications

CyberKnife Prostate

Publications

Videos

CyberKnife Gynecological

Publications

CyberKnife Sarcoma

Publications

TomoTherapy Lung

Publications

TomoTherapy Mesothelioma

Publications

TomoTherapy Liver

Publications

SRS Treatment

CyberKnife for Brain Metastases

Publications

Videos

CyberKnife Other Malignant Tumors

Publications

Videos

CyberKnife Benign Tumors

Publications

Videos

CyberKnife Functional

Publications

Videos

CyberKnife Vascular Lesions

Publications

Videos

CyberKnife Spinal Metastases

Publications

TomoTherapy Intracranial

Publications

Table of Contents